 Silver nanoparticles have antiviral activity against HIV-1 at non-cytotoxic concentrations, and they exert this activity by binding to GP120 and inhibiting viral entry and post-entry stages of the life cycle, making them a broad-spectrum agent that could be used preventively against circulating HIV-1 strains.